Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: Lilly’s latest acquisition; the outlook for Stelara biosimilars; better biomarkers needed in the TIGIT/PD-1 combo field?; Sanofi on the deal-making landscape; and the shifting KRAS race in China.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 23 June 2023, including: Eli Lilly and Company’s latest acquisition; the outlook for Stelara biosimilars; better biomarkers needed in the TIGIT/PD-1 combo field?; Sanofi on the deal-making landscape; and the shifting KRAS race in China.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Lilly Wants To Gamble On Dice’s Oral IL-17 Drugs For Psoriasis" - Scrip, 20 Jun, 2023.)
(Also see "History Repeats: Will US Stelara Settlements Follow Humira’s Lead?" - Scrip, 19 Jun, 2023.)
(Also see "As Gilead’s PD-1/TIGIT Trial Falls Short, Oncologists Say Better Biomarkers Needed" - Scrip, 21 Jun, 2023.)
(Also see "The Dealmaking Landscape According to Sanofi" - Scrip, 15 Jun, 2023.)
(Also see "China’s KRAS Race: Homegrown Contenders Play Catch-Up" - Scrip, 16 Jun, 2023.)